Bay Colony Advisory Group Inc d b a Bay Colony Advisors Sells 4,530 Shares of Pfizer Inc. (NYSE:PFE)

Bay Colony Advisory Group Inc d b a Bay Colony Advisors reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 7.3% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 57,325 shares of the biopharmaceutical company’s stock after selling 4,530 shares during the quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ holdings in Pfizer were worth $1,659,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of PFE. Marshall Wace LLP increased its stake in Pfizer by 279.3% during the 2nd quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company’s stock valued at $150,481,000 after purchasing an additional 8,378,173 shares in the last quarter. Swedbank AB purchased a new stake in shares of Pfizer during the 1st quarter valued at about $172,902,000. International Assets Investment Management LLC purchased a new stake in shares of Pfizer during the 3rd quarter valued at about $146,481,000. Pzena Investment Management LLC boosted its holdings in shares of Pfizer by 181.6% during the 1st quarter. Pzena Investment Management LLC now owns 7,670,445 shares of the biopharmaceutical company’s stock valued at $212,855,000 after acquiring an additional 4,947,000 shares during the last quarter. Finally, Van ECK Associates Corp boosted its holdings in shares of Pfizer by 21.8% during the 1st quarter. Van ECK Associates Corp now owns 15,813,328 shares of the biopharmaceutical company’s stock valued at $438,820,000 after acquiring an additional 2,829,178 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

Pfizer stock traded up $0.37 during mid-day trading on Monday, hitting $28.82. The company had a trading volume of 2,840,389 shares, compared to its average volume of 36,685,988. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $31.54. The company’s fifty day moving average is $29.08 and its 200-day moving average is $28.53. The company has a market capitalization of $163.31 billion, a price-to-earnings ratio of -474.17, a P/E/G ratio of 1.01 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.67 EPS. Equities research analysts predict that Pfizer Inc. will post 2.67 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 5.83%. Pfizer’s payout ratio is -2,800.00%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Citigroup assumed coverage on shares of Pfizer in a report on Friday. They issued a “neutral” rating and a $30.00 price objective on the stock. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. UBS Group raised their price objective on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Finally, Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $33.58.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.